CAS
ACAD icon

Coppell Advisory Solutions’s Acadia Pharmaceuticals ACAD Stock Holding History

Coppell Advisory Solutions’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-4
Closed -$67 – 341
2024
Q4 		$67 Hold
4
– – ﹤0.01% 1921
2024
Q3 		$63 Hold
4
– – ﹤0.01% 1825
2024
Q2 		$65 Buy
+4
New +$65 ﹤0.01% 1745
2023
Q4 		$29K Buy
925
+625
+208% +$14.9K 0.01% 635
2023
Q3 		$4.78K Hold
300
– – ﹤0.01% 721
2023
Q2 		$7.2K Buy
+300
New +$6.67K ﹤0.01% 766
2023
Q1 		– Sell
-600
Closed -$9.55K – 207
2022
Q4 		$9.55K Buy
+600
New +$9.38K ﹤0.01% 620

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
FAM
Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return

Coppell Advisory Solutions's ACAD Position: Q1 2025 in Review

Coppell Advisory Solutions sold out of Acadia Pharmaceuticals (ACAD) in Q1 2025, closing a stake of 4 shares — an estimated $67 sold.

Coppell Advisory Solutions first reported a position in ACAD in Q4 2022 and held it in 7 quarters. The position peaked at $29K in Q4 2023. 320 funds tracked by Wall St. Rank hold ACAD as of Q1 2025.

  • Coppell Advisory Solutions reported no remaining Acadia Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Coppell Advisory Solutions sold 4 Acadia Pharmaceuticals shares in Q1 2025, an estimated $67.
  • Coppell Advisory Solutions first reported a position in Acadia Pharmaceuticals in Q4 2022 and held it in 7 quarters.
  • Coppell Advisory Solutions's Acadia Pharmaceuticals position peaked at $29K in Q4 2023.
  • 320 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2025.

Based on Coppell Advisory Solutions's 13F filing for Q1 2025, filed 16 May 2025.